Laurus Labs Share Price

Q: What is the share price of Laurus Labs Ltd today?

Laurus Labs Ltd share price as on 12 Jun 2026 is ₹1401.6

Pharmaceuticals

NSE: LAURUSLABS Mid Cap ISIN: INE947Q01028

As on 12 June 2026 at 23:50 IST

₹1,401.60

+ 10.80

(0.78%)

Sell Buy

Laurus Labs Ltd. Q1 FY26 Results:

Net profit for the period surged a staggering 1,154% to ₹163 crores in Q1 FY26, from ₹13 crores in Q1 FY25. Total income for the quarter increased 32% year-on-year to ₹1,580 crores, from ₹1,197 crores.

About Laurus Labs Ltd

Laurus Labs Ltd. is a leading research-driven pharmaceutical and biotechnology company. It was founded in the year 2005 by Dr. Satyanarayana Chava. The company has grown to become a significant player in the global pharmaceutical industry. The headquarters of the company is located in Hyderabad, Telangana. Laurus Lab's main products include active pharmaceutical ingredients (APIs), generic formulations, and speciality ingredients. The company also offers contract development and manufacturing organization (CDMO) services. Laurus Labs falls under the pharmaceutical and biotechnology sector. It has a strong market presence in the pharmaceutical industry. +

Over 1 Month

9.79%

Over 6 Months

36.45%

Over 1 Year

105.60%

Over 3 Years

305.01%

Laurus Labs Ltd Summary

Close ₹1,390.80

Open ₹1,385

High ₹1,408.90

Low ₹1,376.60

Volume 15,05,571

Net Turnover (in Cr) ₹210.28

52Wk High ₹1,457

52Wk Low ₹641.05

52Wk High / Low

641.05

1,457

Laurus Labs Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹75,137.91

EPS (TTM) 13.76

Book Value (BV) 97.21

Div. Yield 0.14 %

P/E (TTM) 101.42

Price/Book Value 14.30

Delivery % 52.26 %

Face Value 2

Key Ratios

PE Ratio 72.29

PB Ratio 10.19

EV to Sales 9.13

PEG Ratio 0.76

ROA 9.37

ROE 15.09

Debt-Equity 0.45

Net Profit Margin 12.16

Operating Profit Margin 24.89

Laurus Labs Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	5,629.06	5,067.17	6,046.55	4,950.87	4,837.17
Total Expenses	5,144.77	4,830.81	4,937.61	3,867.02	3,536.06
Profit Before Tax	484.29	236.36	1,108.94	1,083.85	1,301.11
Profit After Tax	354.41	168.21	796.64	832.43	983.82
Operating Profit After Depreciation	700.29	419.26	1,274.11	1,186.24	1,369.27

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	4,123.22	3,890.01	3,408.62	2,652.47	2,170.62
Total Non Current Assets	5,003.25	4,552.06	4,198.72	3,623.43	2,675.83
Total Current Assets	4,332.32	3,834.97	3,461.68	3,344.61	3,074.86
Total Assets	9,335.57	8,387.03	7,660.40	6,968.04	5,750.69
Total Shareholder's Fund	4,472.56	4,110.95	4,037.53	3,351.19	2,597.55

Cash Flow

Particulars (in ₹ Cr.)	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash From Operating Activities	1,623.50	601.65	665.69	993.90	911.10
Net Cash Used In Investing Activities	-1,085.66	-680.33	-822.25	-996.94	-914.47
Net Cash Used In Financing Activities	-524.72	39.28	249.83	-26.64	30.26

Profit and Loss

Particulars (in ₹ Cr.)	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	6,166.50	5,317.45	4,859.81	5,789.40	4,728.59
Total Expenses	5,172.41	4,813.64	4,558.34	4,737.97	3,753.18
Profit Before Tax	994.09	503.81	301.47	1,051.43	975.41
Profit After Tax	740.48	380.39	223.70	760.38	750.09
Operating Profit After Depreciation	1,137.05	686.01	452.29	1,197.13	1,071.27

Balance Sheet

Particulars (in ₹ Cr.)	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Fixed Assets	3,041.05	2,887.50	3,036.31	2,884.16	2,186.23
Total Non Current Assets	5,177.44	4,579.97	4,150.37	3,786.70	3,403.96
Total Current Assets	4,362.59	4,006.78	3,517.11	3,171.26	3,204.57
Total Assets	9,540.03	8,586.75	7,667.48	6,957.96	6,608.53
Total Shareholder's Fund	5,251.94	4,563.95	4,207.05	4,056.82	3,388.21

Cash Flow

Particulars (in ₹ Cr.)	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash From Operating Activities	1,384.95	540.06	658.54	881.55	822.97
Net Cash Used In Investing Activities	-847.06	-591.65	-756.74	-735.27	-836.61
Net Cash Used In Financing Activities	-550.74	59.32	139.41	-185.19	15.19

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	1,811.57	1,778.29	1,653.47	1,569.57	1,720.30
Total Expenses	1,299.46	1,298.08	1,250.21	1,187.44	1,299.70
Profit Before Tax	361.37	326.56	269.73	224.22	312.34
Profit After Tax	281.91	253.11	193.75	161.08	233.87
Operating Profit after Depreciation	523.91	485.97	430.22	392.56	479.17

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	1,580.30	1,509.42	1,566.60	1,432.75	1,650.01
Total Expenses	1,204.94	1,163.56	1,176.94	1,105.37	1,255.18
Profit Before Tax	259.37	234.44	288.84	211.44	330.20
Profit After Tax	191.79	175.08	215.67	157.94	251.90
Operating Profit after Depreciation	388.45	360.23	418.11	348.90	466.99

Laurus Labs Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,375.30

S2 1,359.80

S3 1,343

Pivot 1,392.10

R1 1,407.60

R2 1,424.40

R3 1,439.90

Moving Average

20 SMA 1,374.29

50 SMA 1,223.60

100 SMA 1,117.35

200 SMA 1,038.35

Laurus Labs Ltd Corporate Actions

Laurus Labs Ltd

₹1.2/Share

Announcement Date 08 May 2026

Record Date 08 May 2026

Div Yield 60%

AGM Date: 15 Jul 2021

Outcome of the Board Meeting held on April 29, 2021. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed the summary of the proceedings of the 16th Annual General Meeting held on July 15, 2021. This is for your information and records. (AS Per BSE Announcement Dated on 15.07.2021) Pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201 5, Please find enclosed the voting results (Annexure A) of the Resolutions passed in the 16th Annual general Meeting held on July 15, 2021 along with Scrutinizer Report (Annexure B) on e-voting (remote e-voting and e-voting at the Meeting). (As Per BSE Announcement dated on 16.07.2021) Laurus Labs Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here (As Per BSE Announcement Dated on 17.07.2021)

AGM Date: 30 Jun 2022

Outcome of the Board Meeting - 28.04.2022 Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, this is to inform you that the Register of Members and Share Transfer Books of the Company will remain closed from June 24, 2022 to June 30, 2022 (both days inclusive) for the purpose of 17th Annual General Meeting. The next Annual General Meeting of the Cotnpany shall be held on Thursday, June 30, 2022 at 3.00 pm through Video Conferencing or Other Audio-Visual Means (OVAM) as per the Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. This is to inform all the Stakeholders of the Company that the time of 17th Annual General Meeting of the Company which was erroneously shown as 03.00 PM (IST) on June 30, 2022 may be read as 04.00 PM (1ST). Except for above, there are no changes in any other information declared earlier. Kindly take note of the same. Please find enclosed the newspaper advertisement regarding the 17th Annual General Meeting of the Company to be held through Video Conferencing (VC) and dispatch of Notice and Annual Report through electronic mode on June 06, 2022 as per the circulars issued by the Regulatory Authorities. The Advertisement appeared in the Business Standard (English Newspaper) and Prajasakthi (Telugu Newspaper) on June 09, 2022. (As Per BSE Announcement dated on 09.06.2022) Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed the summary of the proceedings of the 17th Annual General Meeting held on June 30, 2022. Pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed the voting results (Annexure A) of the Resolutions passed in the 17th Annual general Meeting held on June 30, 2022 along with Scrutinizer Report (Annexure B) on voting (remote e-voting and e-voting at the Meeting). (As Per BSE Announcement dated on 30.06.2022)

AGM Date: 14 Jul 2023

Outcome of the Board Meeting held on April 27, 2023 Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, this is to inform you that the Register of Members and Share Transfer Books of the Company will remain closed from July 08, 2023 to July 14, 2023 (both days inclusive) for the purpose of 18th Annual General Meeting. The next Annual General Meeting of the Company shall be held on Friday, July 14, 2023 at 3.00 pm through Video Conferencing or Other Audio-Visual Means (OVAM) as per the Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. Please find enclosed the newspaper advertisement regarding the 18th Annual General Meeting of the Company to be held through Video Conferencing (VC) and proposed dispatch of Notice and Annual Report through electronic mode as per the circulars issued by the Regulatory Authorities. The Advertisement appeared in the Business Standard (English Newspaper) and Prajasakthi (Telugu Newspaper) on June 16, 2023. The same is also available on the Company's website at www.lauruslabs.com. (As per BSE Announcement Dated on 16/06/2023) Pursuant to Regulation 34 of SEBI (LODR) Regulations, 2015, please find enclosed the Notice convening the 18th Annual General Meeting (AGM) of shareholders and the Annual Report for the financial year 2022-23 which will be circulated to the shareholders through electronic mode for the AGM to be held on Friday, July 14, 2023 at 03.00 PM (IST) through video conference (VC). The Notice and the annual report will also be made available on the Company's website at www.lauruslabs.com. Notice of 18th AGM to be held on July 14, 2023 (IST) (As Per BSE Announcement Dated on 21.06.2023) Book closure dates July 08, 2023 to July 14, 2023 (As Per BSE Announcement Dated on 28.06.2023) Voting Results and Scrutinizer Report (As Per BSE Announcement Dated on 15.07.2023)

AGM Date: 11 Jul 2024

11, 2024 at 03.00 PM (IST) through Video Conference and Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Member and Share Transfer Books of the Company will remain closed from July 05, 2024 to July 11, 2024 (both days inclusive) for taking record of the Members of the Company for the purpose of 19th Annual General Meeting. Book Closure for AGM Please find enclosed the summary of the proceedings of the 19th Annual General Meeting held on July 11, 2024. Please find enclosed annexure. (As per BSE Announcement Dated on 11/07/2024)

AGM Date: 26 Jun 2025

Please see annexed enclosure. considered and approved the Notice for convening the 20th Annual General Meeting ('AGM') of the Company on Thursday, June 26, 2025 through Video Conferencing / Other Audio Visual Means. Please see annexed enclosure. (As Per BSE Announcement dated on 03.06.2025) Please see annexed enclosure. Please see annexed enclosure. (As per BSE Announcement Dated on 26/06/2025)

Laurus Labs Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,794.30	₹4,30,512.67
Divis Laboratories Ltd	₹6,651.25	₹1,76,569.79
Torrent Pharmaceuticals Ltd	₹4,570	₹1,54,669.57
Cipla Ltd	₹1,383	₹1,11,725.01
Zydus Lifesciences Ltd	₹1,105.65	₹1,11,254.26

Laurus Labs Ltd Top Mutal Funds Invested

Fund Name	AUM
Mirae Asset ELSS Tax Saver Fund	3.65%
Mirae Asset Midcap Fund	3.45%
Mirae Asset Large & Midcap Fund	2.97%
Invesco India Arbitrage Fund	1.04%
HSBC Small Cap Fund	1.03%

Laurus Labs Ltd News

Laurus Labs allots 3.93 lakh equity shares under ESOP

04 Jun 2026, 06:47 pm

Laurus Labs Ltd spurts 1.14%, up for third straight session

Laurus Labs Ltd is quoting at Rs 1389.5, up 1.14% on the day as on 12:49 IST on the NSE. The stock is up 127.6% in last one year as compared to a 3.32% fall in NIFTY and a 15.48% fall in the Nifty Pharma index.

27 May 2026, 01:05 pm

Laurus Labs Ltd spurts 1.07%, rises for fifth straight session

Laurus Labs Ltd is quoting at Rs 1280.4, up 1.07% on the day as on 12:44 IST on the NSE. The stock is up 115.1% in last one year as compared to a 4.28% drop in NIFTY and a 12.36% drop in the Nifty Pharma.

12 May 2026, 01:00 pm

Laurus Labs Ltd soars 1.75%, Gains for third straight session

Laurus Labs Ltd is quoting at Rs 1227.6, up 1.75% on the day as on 12:49 IST on the NSE. The stock is up 108.49% in last one year as compared to a 0.68% gain in NIFTY and a 14.53% gain in the Nifty Pharma index.

08 May 2026, 01:05 pm

Laurus Labs to hold AGM

On 2 July 2026

30 Apr 2026, 03:41 pm

Laurus Labs Ltd Stock Analysis

Annual revenue for Laurus Labs Ltd increased by 15.97% to ₹6,166.50 crore in FY 2026 from ₹5,317.45 crore in FY 2025.
Annual Net Profit for Laurus Labs Ltd increased by 94.66% to ₹740.48 crore in FY 2026 from ₹380.39 crore in FY 2025.
Promoter Shareholding in Laurus Labs Ltd remains unchanged by 0.00% in the most recent quarter, from 27.49% in December 2025 to 27.49% in March 2026.
Laurus Labs Ltd delivered a 1-year return of 105.60% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
Laurus Labs Ltd share price moved up by 0.78% from its previous close of INR ₹1,390.80. The latest Laurus Labs Ltd share price is INR ₹1,401.60.
Laurus Labs Ltd share price today has been at a low of 1,373.80 and a high of 1,410. Over the past 52 weeks, the Laurus Labs Ltd share price has seen a low of 641.05 and a high of 1,457.

About Laurus Labs Ltd

Laurus Labs Ltd. is a top research-driven pharmaceutical and biotechnology company. The company focuses on the development, manufacture, and sale of active pharmaceutical ingredients (APIs), generic formulations, and speciality ingredients. Laurus Labs also provides contract development and manufacturing organization (CDMO) services. It is catering to both generic and proprietary pharmaceutical markets.
Laurus Labs falls under the pharmaceutical and biotechnology sector. The company was established in 2005 by Dr. Satyanarayana Chava. Since its inception, Laurus Labs has grown to become a significant player in the global pharmaceutical industry. The company is known for its innovation and quality.
The headquarters of Laurus Labs Ltd. is located in Hyderabad, Telangana, India. The company is promoted by Dr. Satyanarayana Chava, who has been instrumental in driving the company's growth and success. He also serves as the CEO and Executive Director of the company. The crucial managerial promoters of the company include:

Ravindranath Kancherla
V V Ravi Kumar
C V Lakshmana Rao
Krishna Chaitanya Chava

Laurus Labs' main products include APIs, generic formulations, and speciality ingredients. The company also offers CDMO services. This service provides end-to-end solutions for pharmaceutical development and manufacturing. Laurus Lab's product portfolio spans various therapeutic areas. This includes antiretrovirals, oncology, cardiovascular, and gastroenterology.
Laurus Labs is one of the largest suppliers of antiretroviral APIs globally. The company's robust capabilities and global reach have positioned it as a key player in the sector. The promoter shareholding in Laurus Labs Ltd. stands at 27.28%. The M/s. NSN Holdings owns a major stake (23.02%) among the total promoter shareholdings. This indicates strong promoter commitment to the business.
The registered office of Laurus Labs Ltd. is located at Vishakapatnam, Andhra Pradesh, 531021, India. Its registrar & transfer agent is KFin Technologies Private Limited.
Laurus Labs Ltd. is a well-established pharmaceutical and biotechnology company in India. The company is known for its comprehensive range of products and strong market presence.

International Base of the Company

Laurus Labs Ltd. is a research-driven pharmaceutical and biotechnology leader. It specializes in active pharmaceutical ingredients (APIs), generic formulations, and specialty ingredients manufacturing. The company combines its development expertise with CDMO services, serving both generic and proprietary pharmaceutical markets through its comprehensive development and manufacturing capabilities.
Global Presence Laurus Labs has established a strong international presence. Its operations span across multiple continents, including North America, Europe, Asia, and Africa. The company's extensive global footprint is a testament to its ability to deliver high-quality pharmaceutical products and services to clients worldwide. Laurus Labs' international base is supported by its strategically located offices, manufacturing facilities, and research and development centres around the world.
Key International Markets Laurus Labs has successfully penetrated key international markets. This includes the United States, Europe, and emerging markets in Asia and Africa. In the United States, the company has a strong presence in the generic formulations market. This is because it supplies a wide range of products to major pharmaceutical companies. Laurus Lab's products are also well-received in Europe. In this country, the company has established long-term partnerships with leading pharmaceutical firms. The company's presence in emerging markets, such as India, China, and South Africa, has further strengthened its global reach and market position.
Manufacturing Capabilities Laurus Labs' international base is further strengthened by its state-of-the-art manufacturing facilities. The company operates many manufacturing plants in India. These are equipped with advanced technology and adhere to stringent quality standards. These facilities are approved by major regulatory authorities, including the US FDA, WHO, and EMA. This ensures the production of high-quality pharmaceutical products that meet global requirements. Laurus Labs' manufacturing capabilities enable it to cater to the diverse needs of its international clients and maintain a competitive edge in the global market.
Research and Development Laurus Labs places a strong emphasis on research and development (R&D). This aids in driving innovation and maintaining its leadership position in the pharmaceutical industry. The company operates multiple R&D centres in India. At this centre, it focuses on developing new and advanced pharmaceutical products. Laurus Labs' R&D efforts are supported by a team of highly skilled scientists and researchers. They work on cutting-edge technologies and methodologies. The company's commitment to R&D has resulted in a robust pipeline of products that cater to the evolving needs of its global clients.
Strategic Partnerships and Alliances Laurus Labs has established strategic partnerships. Also, its alliances with leading global pharmaceutical companies enhance its international operations. These collaborations enable the company to leverage local expertise, access new markets, and deliver innovative solutions to its clients. Laurus Labs has strengthened its position as a trusted global pharmaceutical partner. This is achieved by forming alliances with reputable international firms.
Laurus Labs Ltd. has established a strong international base. It has a presence on multiple continents and a track record of successfully delivering high-quality pharmaceutical products and services worldwide. The company's commitment to innovation, quality, and customer satisfaction has solidified its position as a leading globally. It remains dedicated to delivering world-class pharmaceutical solutions that drive global health and well-being as the company continues to expand its international footprint.